

Karen M Facey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/799493/publications.pdf>

Version: 2024-02-01

29
papers

859
citations

623734

14
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

930
citing authors

#	ARTICLE	IF	CITATIONS
1	Consideration of quality of life in the health technology assessments of rare disease treatments. <i>European Journal of Health Economics</i> , 2022, 23, 645-669.	2.8	7
2	Measuring What Matters: Little Evidence Supporting the Content Validity of EQ-5D in People with Duchenne Muscular Dystrophy and Their Caregivers. <i>Medical Decision Making</i> , 2022, 42, 139-140.	2.4	5
3	Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1674.	2.6	4
4	A framework for action to improve patient and public involvement in health technology assessment. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, .	0.5	5
5	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, .	0.5	8
6	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. <i>Value in Health</i> , 2022, 25, 869-886.	0.3	11
7	Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel. <i>Pharmacoeconomics</i> , 2021, 39, 1021-1044.	3.3	23
8	The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy. <i>Frontiers in Pharmacology</i> , 2021, 12, 699466.	3.5	22
9	The use of nonrandomized evidence to estimate treatment effects in health technology assessment. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1035-1043.	1.4	18
10	Examining the impact of different country processes for appraising rare disease treatments: a case study analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e65.	0.5	7
11	Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 189.	2.7	26
12	Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EUâ€”actions for stakeholders. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 459-468.	0.5	35
13	Stories of Patient Involvement Impact in Health Technology Assessments: A Discussion Paper. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 266-272.	0.5	15
14	As health technology assessment evolves so must its approach to patient involvement. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 549-554.	1.4	7
15	HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries. <i>Health Policy</i> , 2019, 123, 140-151.	3.0	43
16	EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health Technology Assessment. <i>Frontiers in Medicine</i> , 2018, 5, 231.	2.6	47
17	Putting Patients at the Centre of Healthcare: Progress and Challenges for Health Technology Assessments. <i>Patient</i> , 2018, 11, 581-589.	2.7	20
18	EVALUATION OF PATIENT AND PUBLIC INVOLVEMENT INITIATIVES IN HEALTH TECHNOLOGY ASSESSMENT: A SURVEY OF INTERNATIONAL AGENCIES. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 715-723.	0.5	31

#	ARTICLE	IF	CITATIONS
19	Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL). Orphanet Journal of Rare Diseases, 2017, 12, 50.	2.7	72
20	Reflections for Future Development. , 2017, , 419-427.		3
21	Developing the Mosaic of Patient Participation in HTA. , 2017, , 51-66.		7
22	Patient Input to HTA. , 2017, , 67-79.		5
23	IMPROVING THE EFFECTIVENESS AND EFFICIENCY OF EVIDENCE PRODUCTION FOR HEALTH TECHNOLOGY ASSESSMENT. International Journal of Technology Assessment in Health Care, 2015, 31, 201-206.	0.5	27
24	The Imperative for Patient-Centred Research to Develop Better Quality Services in Rare Diseases. Patient, 2015, 8, 1-3.	2.7	5
25	GENERATING HEALTH TECHNOLOGY ASSESSMENT EVIDENCE FOR RARE DISEASES. International Journal of Technology Assessment in Health Care, 2014, 30, 416-422.	0.5	30
26	Patient-focused HTAs. International Journal of Technology Assessment in Health Care, 2011, 27, 273-274.	0.5	14
27	What principles should govern the use of managed entry agreements?. International Journal of Technology Assessment in Health Care, 2011, 27, 77-83.	0.5	123
28	Patients' perspectives in health technology assessment: A route to robust evidence and fair deliberation. International Journal of Technology Assessment in Health Care, 2010, 26, 334-340.	0.5	205
29	Virtual community consultation? Using the literature and weblogs to link community perspectives and health technology assessment. Health Expectations, 2008, 11, 189-200.	2.6	27